Stephen Gist, MD
Internal Medicine · Dallas, TXNPI 1770555450
Payments from drug & device makers
Across 147 payments — averaging $17.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$594
- AbbVie$294
- Novo Nordisk$280
- GSK$147
- Amgen$147
- Boehringer Ingelheim$142
- plus $896 from 24 others
What the payments were for
- Food & beverage$2,501100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 32 | $594 |
| AbbVie | 21 | $294 |
| Novo Nordisk | 17 | $280 |
| GSK | 10 | $147 |
| Amgen | 9 | $147 |
| Boehringer Ingelheim | 7 | $142 |
| Astellas Pharma US Inc | 6 | $124 |
| AstraZeneca | 8 | $115 |
| Abbott | 4 | $95 |
| Madrigal Pharmaceuticals | 3 | $54 |
| Sumitomo Pharma America, Inc. | 2 | $50 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $44 |
| Amarin Pharma, Inc. | 2 | $40 |
| Alnylam Pharmaceuticals Inc. | 2 | $38 |
| Exact Sciences | 2 | $33 |
| Idorsia Pharmaceuticals US Inc | 2 | $30 |
| Sanofi Pasteur Inc. | 2 | $28 |
| Inari Medical, Inc. | 1 | $28 |
| Mayne Pharma Commercial LLC | 1 | $27 |
| Lilly USA, LLC | 2 | $26 |
| Bayer | 2 | $24 |
| Scilex Pharmaceuticals Inc. | 1 | $22 |
| Renalytix AI, Inc. | 1 | $16 |
| VBI Vaccine (delaware) Inc. | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| Antares Pharma, Inc. | 1 | $14 |
| Merck | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
How this compares
$2,501 in reported general payments places this provider in the 80th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 51 | $56,573 |
| EliquisApixaban | 49 | $44,938 |
| XareltoRivaroxaban | 29 | $26,499 |
| JardianceEmpagliflozin | 30 | $24,030 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $14,451 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $14,087 |
| FarxigaDapagliflozin Propanediol | 12 | $7,035 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $2,696 |
| Levothyroxine Sodium | 203 | $2,550 |
| SynthroidLevothyroxine Sodium | 27 | $2,028 |
| Atorvastatin Calcium | 159 | $2,004 |
| Celecoxib | 34 | $1,664 |
| Tamsulosin Hcl | 80 | $1,647 |
| Amlodipine Besylate | 193 | $1,165 |
| Lisinopril | 147 | $1,108 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $280 | $56,57351 claims |
| PfizerEliquis | $594 | $44,93849 claims |
| Johnson & JohnsonXarelto | $14 | $26,49929 claims |
| Boehringer IngelheimJardiance | $142 | $24,03030 claims |
| GSKTrelegy Ellipta | $147 | $14,08714 claims |
| AstraZenecaFarxiga | $115 | $7,03512 claims |
| AbbVieSynthroid | $294 | $2,02827 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Dallas
- Amit VermaDallas$7.7M
- Valentine EbuhDallas$6.8M
- Gary SinclairDallas$3.4M
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.